Novo gets the green light for once-daily haemophilia drug following setbacks
The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.
The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.
What's Your Reaction?
